.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Federal Trade Commission
McKinsey
QuintilesIMS
Cipla
Healthtrust
Covington
Johnson and Johnson
Deloitte
Mallinckrodt

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,420,676

« Back to Dashboard

Which drugs does patent 8,420,676 protect, and when does it expire?


Patent 8,420,676 protects SIVEXTRO and is included in two NDAs.

This patent has thirty-two patent family members in twenty-one countries.

Summary for Patent: 8,420,676

Title:Oxazolidinone derivatives
Abstract: The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as, Staphylococci, Enterococci and Streptococci anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.
Inventor(s): Rhee; Jae Keol (Kyonggido, KR), Im; Weon Bin (Yongin-si, KR), Cho; Chong Hwan (Yongin-si, KR), Choi; Sung Hak (Seongnam-si, KR), Lee; Tae Ho (Yongin-si, KR)
Assignee: Dong-A Pharmaceuticals Co. Ltd. (Seoul, KR)
Application Number:12/211,655
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cubist Pharms Llc
SIVEXTRO
tedizolid phosphate
TABLET;ORAL205435-001Jun 20, 2014RXYesYes8,420,676► SubscribeYY METHOD OF TREATING BACTERIAL INFECTIONS
Cubist Pharms Llc
SIVEXTRO
tedizolid phosphate
POWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes8,420,676► SubscribeYY METHOD OF TREATING BACTERIAL INFECTIONS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,420,676

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2003-0093342Dec 18, 2003
South Korea10-2004-0058809Jul 27, 2004

Non-Orange Book Patents for Patent: 8,420,676

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,816,379Oxazolidinone derivatives► Subscribe
9,163,043Oxazolidinone derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,420,676

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2006125761► Subscribe
Portugal1699784► Subscribe
New Zealand575842► Subscribe
New Zealand547928► Subscribe
Netherlands300759► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Moodys
QuintilesIMS
Accenture
Queensland Health
McKesson
Fish and Richardson
Healthtrust
UBS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot